Loading clinical trials...
Loading clinical trials...
An Open-Label, Dose-Escalating Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease
Conditions
Interventions
Cysteamine Bitartrate
Locations
5
United States
University of California at San Diego (UCSD)
San Diego, California, United States
Stanford University
Stanford, California, United States
Akron Children's Hospital
Akron, Ohio, United States
Baylor College of Medicine
Houston, Texas, United States
University of Utah, Division of Medical Genetics
Salt Lake City, Utah, United States
Start Date
May 1, 2014
Primary Completion Date
October 1, 2016
Completion Date
October 1, 2016
Last Updated
December 27, 2024
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions